MAGE1 Is Expressed by a Subset of Pancreatic Endocrine Neoplasms and Associated Lymph Node and Liver Metastases

Donna E. Hansel, Michael House, Raheela Ashfaq, Ayman Rahman, Charles J. Yeo, Anirban Maitra

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. MAGE1 was originally isolated from human melanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. Aim of the Study. To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. Methods. We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1 (minimally detectable expression), 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. Results. We have identified MAGE1 expression in a subset (42 of 49; 86%) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). Conclusions. MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.

Original languageEnglish (US)
Pages (from-to)141-147
Number of pages7
JournalInternational Journal of Gastrointestinal Cancer
Volume33
Issue number2-3
StatePublished - 2003
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Lymph Nodes
Neoplasm Metastasis
Liver
Germ Cell and Embryonal Neoplasms
Pancreatic Ducts
Testicular Neoplasms
Autoantigens
Cytotoxic T-Lymphocytes
Melanoma
Vaccines
Cell Count
Breast Neoplasms
Survival

Keywords

  • Gastrinoma
  • Insulinoma
  • Liver
  • Metastasis
  • Pancreas
  • Tumor

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology
  • Oncology

Cite this

MAGE1 Is Expressed by a Subset of Pancreatic Endocrine Neoplasms and Associated Lymph Node and Liver Metastases. / Hansel, Donna E.; House, Michael; Ashfaq, Raheela; Rahman, Ayman; Yeo, Charles J.; Maitra, Anirban.

In: International Journal of Gastrointestinal Cancer, Vol. 33, No. 2-3, 2003, p. 141-147.

Research output: Contribution to journalArticle

Hansel, Donna E. ; House, Michael ; Ashfaq, Raheela ; Rahman, Ayman ; Yeo, Charles J. ; Maitra, Anirban. / MAGE1 Is Expressed by a Subset of Pancreatic Endocrine Neoplasms and Associated Lymph Node and Liver Metastases. In: International Journal of Gastrointestinal Cancer. 2003 ; Vol. 33, No. 2-3. pp. 141-147.
@article{d0bdb4c6677748318277c9b754239bef,
title = "MAGE1 Is Expressed by a Subset of Pancreatic Endocrine Neoplasms and Associated Lymph Node and Liver Metastases",
abstract = "Background. MAGE1 was originally isolated from human melanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. Aim of the Study. To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. Methods. We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1 (minimally detectable expression), 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. Results. We have identified MAGE1 expression in a subset (42 of 49; 86{\%}) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). Conclusions. MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.",
keywords = "Gastrinoma, Insulinoma, Liver, Metastasis, Pancreas, Tumor",
author = "Hansel, {Donna E.} and Michael House and Raheela Ashfaq and Ayman Rahman and Yeo, {Charles J.} and Anirban Maitra",
year = "2003",
language = "English (US)",
volume = "33",
pages = "141--147",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
number = "2-3",

}

TY - JOUR

T1 - MAGE1 Is Expressed by a Subset of Pancreatic Endocrine Neoplasms and Associated Lymph Node and Liver Metastases

AU - Hansel, Donna E.

AU - House, Michael

AU - Ashfaq, Raheela

AU - Rahman, Ayman

AU - Yeo, Charles J.

AU - Maitra, Anirban

PY - 2003

Y1 - 2003

N2 - Background. MAGE1 was originally isolated from human melanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. Aim of the Study. To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. Methods. We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1 (minimally detectable expression), 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. Results. We have identified MAGE1 expression in a subset (42 of 49; 86%) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). Conclusions. MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.

AB - Background. MAGE1 was originally isolated from human melanoma cells as a target antigen for autologous cytotoxic T lymphocytes. Expression of MAGE1 has subsequently been identified in a number of neoplastic cell types, including testicular germ cell and breast cancer cells, which has led to the development of antitumor MAGE1 vaccines. Aim of the Study. To determine if Mage-1 is expressed in pancreatic endocrine neoplasms (PENs) and PEN metastases. Methods. We utilized immunolabeling analysis for Mage-1 on 49 primary PENs, 11 liver metastases, and 6 lymph node metastases. A semiquantitative labeling index (LI) of 0 (no expression), 1 (minimally detectable expression), 2 (moderate expression), and 3 (intense expression, correlating with internal control markers) was used to determine relative amounts of MAGE1 expression in these lesions. Results. We have identified MAGE1 expression in a subset (42 of 49; 86%) of PENs. Normal pancreatic ducts, present in tissue adjacent to PENs, were utilized as a positive control for Mage-1 immunolabeling (index score 3); no other detectable labeling for Mage-1 was evident in normal pancreatic tissue. Primary PENs, with or without metastases (mean LI score 1.2 vs 1.0, respectively), did not demonstrate a significant difference in Mage-1 LI, although intratumoral heterogeneity was apparent in some, but not all, of these lesions. Lymph node metastases (mean score 2.0) demonstrated a significant increase in Mage-1 LI as compared to primary, non-metastatic lesions (p = 0.04984) and primary metastatic lesions (p = 0.02351). In contrast, six patients with a survival of less than one year demonstrated a low Mage-1 LI (mean score, 0.58). Conclusions. MAGE1 expression is present in a subset of primary PENs and in lymph node metastases, and may therefore serve as a useful marker and potential therapeutic target in PENs. Furthermore, the absence of Mage-1 expression in a subset of primary PENs may indicate a worsened prognosis.

KW - Gastrinoma

KW - Insulinoma

KW - Liver

KW - Metastasis

KW - Pancreas

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0347478261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347478261&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 141

EP - 147

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

IS - 2-3

ER -